AgenusInc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study evaluating botensilimab (BOT), Agenus’ multifunctional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results